| Realtime | Geld | Brief | Zeit |
|---|---|---|---|
| 34,025 | 34,480 | 22.04. | |
| 34,040 | 34,475 | 22.04. |
| Stück | Geld | Kurs | Brief | Stück |
|---|---|---|---|---|
| 40,400 | 125 | |||
| 39,360 | 150 | |||
| 39,000 | 5 | |||
| 38,600 | 450 | |||
| 38,300 | 150 | |||
| 36,880 | 70 | |||
| 36,800 | 165 | |||
| 36,200 | 130 | |||
| 34,495 | 1.152 | |||
| 34,475 | 227 | |||
Quelle: [URL] https://aktienkurs-orderbuch.finanznachrichten.de/qia.htm [/URL] | ||||
| 1.379 | 34,040 | |||
| 960 | 34,000 | |||
| 75 | 33,930 | |||
| 50 | 33,050 | |||
| 50 | 33,000 | |||
| 300 | 32,120 | |||
| 1.086 | 0,000 | |||
| Summe Aktien im Kauf | Verhältnis | Summe Aktien im Verkauf | ||
| 3.900 | 0,673 | 2.624 | ||
| Uhrzeit | Aktienkurs | Stück |
|---|---|---|
| 17:35:25 | 34,075 | 207.088 |
| 17:29:59 | 34,105 | 78 |
| 17:29:59 | 34,100 | 125 |
| 17:29:59 | 34,100 | 105 |
| 17:29:49 | 34,115 | 1 |
| 17:29:49 | 34,105 | 43 |
| 17:29:14 | 34,100 | 57 |
| 17:29:14 | 34,100 | 20 |
| 17:29:14 | 34,100 | 36 |
| 17:29:14 | 34,100 | 43 |
| 17:29:14 | 34,100 | 80 |
| 17:29:13 | 34,090 | 47 |
| 17:29:07 | 34,080 | 56 |
| 17:29:00 | 34,090 | 1 |
| 17:29:00 | 34,085 | 147 |
| 17:28:58 | 34,090 | 320 |
| 17:28:24 | 34,090 | 1 |
| 17:28:08 | 34,075 | 218 |
| 17:27:40 | 34,070 | 144 |
| 17:27:40 | 34,070 | 8 |
| Tagesumsatz Xetra | -0,625 -1,80 % | 378.563 |
Angaben in grüner Schrift zeigen, dass der Aktienkurs im Vergleich zum vorherigen Kurs gestiegen ist. Angaben in roter Schrift zeigen gefallene Börsenkurse.
| Zeit | Aktuelle Nachrichten Sprache:
Alle DE EN | Leser | Medien | ||
|---|---|---|---|---|---|
| Di | Aktien New York Ausblick: Moderate Gewinne - Lage in Nahost sorgt für Vorsicht | 516 | dpa-AFX | NEW YORK (dpa-AFX) - Am US-Aktienmarkt werden am Dienstag zum Handelsstart moderate Gewinne erwartet. Angesichts der unsicheren Lage in Nahost dominiert - wie bereits zum Wochenstart - die Vorsicht.... ► Artikel lesen | |
| 16.04. | QIAGEN N.V.: QIAGEN to Showcase New Sample to Insight Solutions for Complex Oncology Applications at AACR 2026 | 516 | Business Wire | Highlights solutions addressing key oncology research needs across automated sample preparation, single-cell analysis, genomic profiling and data analysis QIAsymphony Connect will serve... ► Artikel lesen | |
| 15.04. | QIAGEN NV - Stabilität als strategische Basis | 33 | Maximilian Berger | ||
| 14.04. | Qiagen erweitert Portfolio um Test für Blutstrominfektionen | 15 | Investing.com Deutsch | ||
| QIAGEN Aktie jetzt für 0€ handeln | |||||
| 14.04. | Qiagen launches bloodstream infection testing panel | 7 | Investing.com |
| Zeit | Aktuelle Nachrichten | Medien | ||
|---|---|---|---|---|
| Mi | Morning Market Movers: Axe Compute, Inhibrx Biosciences, Huachen AI Parking Management Technology, 1-800-FLOWERS.COM See Big Swings | AFX News | OTTAWA (dpa-AFX) - At 9:00 a.m. ET on Wednesday, premarket trading is seeing notable activity in several stocks, with early price movements signaling potential opportunities before the opening... ► Artikel lesen | |
| Mi | Humacyte, Inc: Humacyte Appoints Jim Mercadante as Chief Commercial Officer | GlobeNewswire (Europe) | - Industry veteran with more than 25 years of experience will lead next phase of biotech company's commercial expansion - - Seasoned medtech commercial leader brings extensive field-specific success... ► Artikel lesen | |
| Mi | Degroof Petercam Initiates Medincell's Coverage with a "Buy" Recommendation | Business Wire | Degroof Petercam, a leading European investment bank with strong healthcare expertise, has initiated coverage of Medincell In a report entitled "Royalty flywheel approaching profitability", the... ► Artikel lesen | |
| Mi | RedHill Biopharma Ltd.: RedHill's Opaganib Enhances Efficacy of Neuroblastoma Chemo Combination and Augment Anti-Tumor Immunity in Triple-Negative Breast Cancer in Preclinical Studies - New Data Presented at AACR 2026 | PR Newswire | New preclinical data, independently presented in two posters at the 2026 American Association for Cancer Research (AACR) Annual Meeting, show positive effects of... ► Artikel lesen | |
| Mi | NurExone legt Zahlen vor - und treibt seine Schlüsseltechnologie weiter voran | Small- & Micro Cap Investment |